For cell and gene therapy, a consistent supply of quality starting material is vital that is maintained throughout the ...

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic ...

Completed biopharma IPOs that raised more than $100 million saw a twofold increase during the year. Biopharmaceutical initial ...

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...